Cimica et al. BMC Cancer 2010, 10:634 http://www.biomedcentral.com/1471-2407/10/634 interpreted the data, prepared the manuscript, and provided guidance for the entire study. All authors read and approved the final manuscript. Competing interests The authors declare that they have no competing interests. Received: 11 November 2009 Accepted: 19 November 2010 Published: 19 November 2010 References 1. Biegel JA: Molecular genetics of atypical teratoid/rhabdoid tumor. Neurosurg Focus 2006, 20(1):E11. 2. Reddy AT: Atypical teratoid/rhabdoid tumors of the central nervous system. J Neurooncol 2005, 75(3):309-313. 3. Strother D: Atypical teratoid rhabdoid tumors of childhood: diagnosis, treatment and challenges. Expert Rev Anticancer Ther 2005, 5(5):907-915. 4. Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Merchant TE, Krasin M, Dalton J, Hale G, Kun LE, et al: Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children 3 years of age and older with radiation therapy and high-dose alkylator-based chemotherapy. J Clin Oncol 2005, 23(7):1491-1499. 5. Biegel JA, Zhou JY, Rorke LB, Stenstrom C, Wainwright LM, Fogelgren B: Germ-line and acquired mutations of INI1 in atypical teratoid and rhabdoid tumors. Cancer Res 1999, 59(1):74-79. 6. Versteege I, Sevenet N, Lange J, Rousseau-Merck MF, Ambros P, Handgretinger R, Aurias A, Delattre O: Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer. Nature 1998, 394(6689):203-206. 7. Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE: Re- expression of hSNF5/INI1/BAF47 in pediatric tumor cells leads to G1 arrest associated with induction of p16ink4a and activation of RB. Oncogene 2002, 21(34):5193-5203. 8. Versteege I, Medjkane S, Rouillard D, Delattre O: A key role of the hSNF5/ INI1 tumour suppressor in the control of the G1-S transition of the cell cycle. Oncogene 2002, 21(42):6403-6412. 9. Zhang ZK, Davies KP, Allen J, Zhu L, Pestell RG, Zagzag D, Kalpana GV: Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol 2002, 22(16):5975-5988. 10. Chai J, Charboneau AL, Betz BL, Weissman BE: Loss of the hSNF5 gene concomitantly inactivates p21CIP/WAF1 and p16INK4a activity associated with replicative senescence in A204 rhabdoid tumor cells. Cancer Res 2005, 65(22):10192-10198. 11. Alarcon-Vargas D, Zhang Z, Agarwal B, Challagulla K, Mani S, Kalpana GV: Targeting cyclin D1, a downstream effector of INI1/hSNF5, in rhabdoid tumors. Oncogene 2006, 25(5):722-734. 12. Tsikitis M, Zhang Z, Edelman W, Zagzag D, Kalpana GV: Genetic ablation of Cyclin D1 abrogates genesis of rhabdoid tumors resulting from Ini1 loss. Proc Natl Acad Sci USA 2005, 102(34):12129-12134. 13. Smith ME, Cimica V, Chinni S, Challagulla K, Mani S, Kalpana GV: Rhabdoid tumor growth is inhibited by flavopiridol. Clin Cancer Res 2008, 14(2):523-532. 14. Byrd JC, Lin TS, Dalton JT, Wu D, Phelps MA, Fischer B, Moran M, Blum KA, Rovin B, Brooker-McEldowney M, et al: Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia. Blood 2007, 109(2):399-404. 15. Whitlock JA, Krailo M, Reid JM, Ruben SL, Ames MM, Owen W, Reaman G: Phase I clinical and pharmacokinetic study of flavopiridol in children with refractory solid tumors: a Children’s Oncology Group Study. J Clin Oncol 2005, 23(36):9179-9186. 16. Carlson B, Lahusen T, Singh S, Loaiza-Perez A, Worland PJ, Pestell R, Albanese C, Sausville EA, Senderowicz AM: Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Cancer Res 1999, 59(18):4634-4641. 17. Chao SH, Price DH: Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 2001, 276(34):31793-31799. 18. Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, Peterlin BM, Price DH: Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000, 275(37):28345-28348. 19. de Azevedo WF Jr, Canduri F, da Silveira NJ: Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. Biochem Biophys Res Commun 2002, 293(1):566-571. Page 12 of 13 20. Takada Y, Aggarwal BB: Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 2004, 279(6):4750-4759. 21. Cappellini A, Tabellini G, Zweyer M, Bortul R, Tazzari PL, Billi AM, Fala F, Cocco L, Martelli AM: The phosphoinositide 3-kinase/Akt pathway regulates cell cycle progression of HL60 human leukemia cells through cytoplasmic relocalization of the cyclin-dependent kinase inhibitor p27 (Kip1) and control of cyclin D1 expression. Leukemia 2003, 17(11):2157-2167. 22. Liang J, Slingerland JM: Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003, 2(4):339-345. 23. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJ, Lam EW, Burgering BM, Medema RH: Cell cycle inhibition by FoxO forkhead transcription factors involves downregulation of cyclin D. Mol Cell Biol 2002, 22(22):7842-7852. 24. Wu K, Wang C, D’Amico M, Lee RJ, Albanese C, Pestell RG, Mani S: Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol Cancer Ther 2002, 1(9):695-706. 25. Sedlacek HH: Mechanisms of action of flavopiridol. Crit Rev Oncol Hematol 2001, 38(2):139-170. 26. Demidenko ZN, Blagosklonny MV: Flavopiridol induces p53 via initial inhibition of Mdm2 and p21 and, independently of p53, sensitizes apoptosis-reluctant cells to tumor necrosis factor. Cancer Res 2004, 64(10):3653-3660. 27. Puppo M, Pastorino S, Melillo G, Pezzolo A, Varesio L, Bosco MC: Induction of apoptosis by flavopiridol in human neuroblastoma cells is enhanced under hypoxia and associated with N-myc proto-oncogene down- regulation. Clin Cancer Res 2004, 10(24):8704-8719. 28. Newcomb EW, Tamasdan C, Entzminger Y, Alonso J, Friedlander D, Crisan D, Miller DC, Zagzag D: Flavopiridol induces mitochondrial- mediated apoptosis in murine glioma GL261 cells via release of cytochrome c and apoptosis inducing factor. Cell Cycle 2003, 2(3):243-250. 29. Fornier MN, Rathkopf D, Shah M, Patil S, O’Reilly E, Tse AN, Hudis C, Lefkowitz R, Kelsen DP, Schwartz GK: Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res 2007, 13(19):5841-5846. 30. Karp JE, Smith BD, Levis MJ, Gore SD, Greer J, Hattenburg C, Briel J, Jones RJ, Wright JJ, Colevas AD: Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin Cancer Res 2007, 13(15 Pt 1):4467-4473. 31. Stendahl M, Kronblad AA, Ryden L, Emdin S, Bengtsson NO, Landberg G: Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 2004, 90(10):1942-1948. 32. Christov KT, Shilkaitis AL, Kim ES, Steele VE, Lubet RA: Chemopreventive agents induce a senescence-like phenotype in rat mammary tumours. Eur J Cancer 2003, 39(2):230-239. 33. Han S, Park K, Bae BN, Kim KH, Kim HJ, Kim YD, Kim HY: Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer. Oncol Rep 2003, 10(1):141-144. 34. Kenny FS, Hui R, Musgrove EA, Gee JM, Blamey RW, Nicholson RI, Sutherland RL, Robertson JF: Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer. Clin Cancer Res 1999, 5(8):2069-2076. 35. Jang TJ, Park JH, Cho MY, Kim JR: Chemically induced rat mammary tumor treated with tamoxifen showed decreased expression of cyclin D1, cyclin E, and p21(Cip1). Cancer Lett 2001, 170(2):109-116. 36. Lee TH, Chuang LY, Hung WC: Tamoxifen induces p21WAF1 and p27KIP1 expression in estrogen receptor-negative lung cancer cells. Oncogene 1999, 18(29):4269-4274. 37. Koshida S, Narita T, Kato H, Yoshida S, Taga T, Ohta S, Takeuchi Y: Estrogen receptor expression and estrogen receptor-independent cytotoxic effects of tamoxifen on malignant rhabdoid tumor cells in vitro. Jpn J Cancer Res 2002, 93(12):1351-1357. 38. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, Sedivy JM, Kinzler KW, Vogelstein B: Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998, 282(5393):1497-1501.